Evidence-Based Complementary and Alternative Medicine

Research Article

Study on the Potential Mechanism of Fructus Tribuli in the Treatment of Hypertensive Vascular Remodeling Based on Network Pharmacology and Molecular Docking

LibDock scores of major active compound-main target molecular docking.


Number	Compounds	LibDock Score
Number	Compounds	AKT1	MAPK3	VEGFA	SRC	IL6

FT3	Kaempferol	60.87	68.44	86.37	70.98	0.00
FT1	Isorhamnetin	60.50	112.15	123.48	92.79	67.24
FT11	(2aR,2’S,4R,4’R,5’S,6aS,6bS,8aS,8bR,9S,11aR,12aR,12bR)-4,4’-dihydroxy-5’,6a,8a,9-tetramethylicosahydro-1H-spiro[pentaleno[2,1-a]phenanthrene-10,2’-pyran]-8(2H)-one	0.00	0.00	81.20	0.00	72.51
FT4	(Z)-3-(4-hydroxy-3-methoxy-phenyl)-N-[2-(4-hydroxyphenyl)ethyl]acrylamide	94.50	110.96	94.66	99.70	85.32
FT10	Terrestriamide	0.00	0.00	96.83	96.77	88.63
FT14	Tigogenin	123.52	104.95	118.77	81.80	79.52
FT6	(3R,8S,9S,10R,13R,14R,17S)-17-((2S,5R)-5-ethyl-6-methylheptan-2-yl)-3-hydroxy-10,13-dimethyl-3,4,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-7(2H)-one	127.07	62.24	116.71	110.59	83.07
FT8	(Z)-3-(3,4-dihydroxyphenyl)-N-[2-(4-hydroxyphenyl)ethyl]acrylamide	90.15	107.96	93.94	89.87	88.15
FT13	Hecogenin	0.00	0.00	76.87	0.00	0.00
FT7	(3R,7R,8S,9S,10S,13R,14S,17R)-17-((2R,5S)-5-ethyl-6-methylheptan-2-yl)-3,10-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-7-ol	95.34	113.95	94.71	87.17	92.55
FT2	Sitosterol	0.00	0.00	108.59	55.55	61.00
FT15	Terrestrosin D	0.00	0.00	151.75	167.11	0.00
—	Ligand	86.31	88.48	47.65	133.52	72.78